- Geoffrey just donated $52.50
- Stephen just donated $2,100
- Stephen just donated $1,050
- Michelle just donated $25
- Christine just donated $25
- Duncan just donated $35
- Daheng just donated $50
- Theresa Green just donated $25
- Lisa Dingwall just donated $50
- Sheree just donated $50
- Sofie just donated $25
- simone just donated $50
- Tanya just donated $25
- Jacqui just donated $50
- Rebecca just donated $25
- John just donated $25
- Chris just donated $25
- John just donated $25
- Damien just donated $25
- Courtney just donated $25
About Prostate Cancer
In Australia, prostate cancer is the most commonly diagnosed cancer in men. Approximately 3,500 Australian men die of prostate cancer each year. This cancer does not produce symptoms until it is advanced, so early diagnosis is currently made indirectly through the PSA blood test.
- One in 7 men will be diagnosed with prostate cancer by the age of 85.
- It is more common in older men, with 63% of cases diagnosed in men over 65 years of age.
- More men die of prostate cancer than women die of breast cancer.
- 30% of patients who undergo radical prostatectomy, the commonest form of treatment for clinically localised disease, have secondary cancer diagnosed subsequently.
The ImmunoPro Project
The vision of our medical research is to develop a therapeutic vaccine for all prostate cancer patients
The ImmunoPro project aims to develop a therapeutic vaccine for all prostate cancer patients. The research project will herald in a new treatment paradigm for prostate cancer using the body’s own natural immune defences to fight the most common cancer in men.
As routine treatment, those men at high risk of cancer escape will have lymph nodes and prostate cancer removed by prostatectomy, and used to develop a personalised activation of the patient’s immune system. We have refined this DC immunotherapy approach to be more effective and less resource-intensive than prior applications.
When incurable recurrent cancer is detected by an elevated PSA test following a prostatectomy, participants will receive their vaccines to target microscopic cancer cells undetectable by imaging, providing the optimal scenario for cure at a time tumour burden is very low and patients are feeling well.
We are also developing a new approach to diagnose aggressive, potentially life-threatening disease to identify those likely to have microscopic cancer escape. This test involves detecting cellular exosomes and will complement other research being undertaken with co-investigators at XING Technologies to identify prostate cancer cells.
Prior to vaccine treatment, essential optimisation is required to maximise efficacy and safety for personalised treatment. This preparatory phase will take up to three years.
Through strengths in diagnostic testing, modern cancer imaging and clinical trials, this research will ensure an impactful outcome to benefit men worldwide.
Our group members are internationally recognised as experts in prostate cancer studies, with DCs in particular, at both clinical and pre-clinical levels. The next step is to undertake the proposed research as an immediate precedent to patient treatment.
Make a Donation to Support Prostate Cancer
All donations over $2 are tax deductible